Back to search

Peptide record

TPDB41428

p369-CTL-A2xFVB p369-CTL-A2xneu Anticancer Tumor T cell antigens standard
9 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB41428
p369-CTL-A2xFVB p369-CTL-A2xneu
Anticancer Tumor T cell antigens
Cancer-related peptides
AntiCP 2.0 CancerPPD 2.0 Peptipedia SATPdb dbACP iACP-DRLF ENCAP iTTCA-Hybrid iTTCA-RF LYnet-master
standard
No
A 9-aa standard natural multi-activity (Anticancer and Tumor T cell antigens) peptide sequence curated from AntiCP 2.0, CancerPPD 2.0, Peptipedia, and other sources, with an available 3D structural model.
Sequence
KIFGSLAFL
Physicochemical Analysis
C50H78N10O11
RNDCEQHMPTWYV
LF
995.23
10.10
1
0
6
+1
-2.73
1.600
141.11
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
0
0.00
1
Residue Composition
number
1
A
0
R
0
N
0
D
0
C
0
E
0
Q
1
G
0
H
1
I
2
L
1
K
0
M
2
F
0
P
1
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 1 L: 2 K: 1 M: 0 F: 2 P: 0 S: 1 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
9
C50H78N10O11
995.23
10.10
+1
-2.73
1.600
Free
L
Linear
Free
Antitumor
Synthetic Peptide
Evidence Records 14 records
Evidence 1 Activity

Activity

0.1% Inhibition at 10-10 M
Anticancer

Target

Tumor
N202.A2
Not Available

Assay & Model

Peptide dose curve assay
Not Available

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2004

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

1% Inhibition at 10-9 M
Anticancer

Target

Tumor
N202.A2
Not Available

Assay & Model

Peptide dose curve assay
Not Available

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2004
Evidence 3 Activity

Activity

5% Inhibition at 10-8 M
Anticancer

Target

Tumor
N202.A2
Not Available

Assay & Model

Peptide dose curve assay
Not Available

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2004
Evidence 4 Activity

Activity

10% Inhibition at 10-7 M
Anticancer

Target

Tumor
N202.A2
Not Available

Assay & Model

Peptide dose curve assay
Not Available

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2004
Evidence 5 Activity

Activity

20% Inhibition at 10-6 M
Anticancer

Target

Tumor
N202.A2
Not Available

Assay & Model

Peptide dose curve assay
Not Available

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2004
Evidence 6 Activity

Activity

8% Inhibition at 10-10 M
Anticancer

Target

Tumor
N202.A2
Not Available

Assay & Model

Peptide dose curve assay
Not Available

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2004
Evidence 7 Activity

Activity

25% Inhibition at 10-9 M
Anticancer

Target

Tumor
N202.A2
Not Available

Assay & Model

Peptide dose curve assay
Not Available

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2004
Evidence 8 Activity

Activity

80% Inhibition at 10-8 M
Anticancer

Target

Tumor
N202.A2
Not Available

Assay & Model

Peptide dose curve assay
Not Available

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2004
Evidence 9 Activity

Activity

85% Inhibition at 10-7 M
Anticancer

Target

Tumor
N202.A2
Not Available

Assay & Model

Peptide dose curve assay
Not Available

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2004
Evidence 10 Activity

Activity

92% Inhibition at 10-6 M
Anticancer

Target

Tumor
N202.A2
Not Available

Assay & Model

Peptide dose curve assay
Not Available

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2004
Evidence 11 Activity

Activity

Tumor T cell antigens

Assay & Model

in vitro

Source & Reference

NA
TANTIGEN/TADB

Other

T-cell epitope
A*0201
Overexpressed antigen
Overexpressed antigen
Evidence 12 Activity

Activity

Tumor T cell antigens

Assay & Model

in vitro

Source & Reference

NA
TANTIGEN/TADB

Other

T-cell epitope
A*0202
Overexpressed antigen
Overexpressed antigen
Evidence 13 Activity

Activity

Tumor T cell antigens

Assay & Model

in vitro

Source & Reference

NA
TANTIGEN/TADB

Other

T-cell epitope
A*0203
Overexpressed antigen
Overexpressed antigen
Evidence 14 Activity

Activity

Tumor T cell antigens

Assay & Model

in vitro

Source & Reference

NA
TANTIGEN/TADB

Other

T-cell epitope
A*0206
Overexpressed antigen
Overexpressed antigen
Additional Detail Fields 3 fields
Overexpressed antigen
Overexpressed antigen
A*0201 A*0202 A*0203 A*0206